FOX2 antibodies are specialized reagents targeting the FOX2 protein, also known as RNA Binding Fox-1 Homolog 2 (RBFOX2) or RNA Binding Motif Protein 9 (RBM9). These antibodies are critical tools for studying FOX2's role in mRNA splicing, synaptic plasticity, and cellular differentiation. FOX2 regulates alternative splicing of pre-mRNA, influencing diverse biological processes, including neurodevelopment and fibrosis .
FOX2 is a 41 kDa RNA-binding protein localized in the nucleus and cytoplasm. Key features include:
Function: Mediates alternative splicing, mRNA stability, and transcriptional regulation .
Expression: Ubiquitous, with high levels in brain, heart, and reproductive tissues .
Clinical Relevance: Implicated in cancer, fibrosis, and neurodevelopmental disorders .
FOX2 antibodies are widely used in:
Western Blot (WB): Detects FOX2 at ~41–50 kDa (varies by isoform) .
Immunohistochemistry (IHC): Localizes FOX2 in nuclei of Purkinje cells and cancer tissues .
Immunofluorescence (IF): Visualizes FOX2 in neuronal and epithelial cells .
Knockdown/Overexpression Studies: Validates FOX2's role in splicing regulation .
Study: FOX2 knockdown in scleroderma fibroblasts reduced LH2(long) mRNA, a fibrosis-associated isoform .
Mechanism: FOX2 binds UGCAUG motifs upstream of exon 13A in LH2 pre-mRNA to promote inclusion .
Tools: siRNA and FOX2 antibodies (e.g., ab57154) confirmed splicing modulation .
CLIP-seq Analysis: FOX2 binds 962 sites in FGFR2 pre-mRNA, regulating exon inclusion critical for stem cell pluripotency .
Functional Impact: FOX2 depletion triggered apoptosis in human embryonic stem cells .
Expression: FOX2 is enriched in cerebellar Purkinje cells and cortical neurons .
Validation: Neuromics' CH22130 antibody highlighted FOX2's nuclear localization in mouse brain sections .
FOX2 antibodies are rigorously validated across platforms:
Here’s a structured FAQ collection for researchers working with FOX2 (RBFOX2) antibodies, synthesized from academic literature, patent data, and experimental protocols:
Advanced Considerations:
Negative controls: Use non-targeting IgG in IP assays to rule out nonspecific RNA binding .
Splicing reporters: Design minigenes containing UGCAUGU motifs to assess FOX2-dependent exon skipping/inclusion .
Expression normalization: Co-stain with RNA-binding proteins like MBNL1/2 to control for technical variability .
Troubleshooting Framework:
Fixation artifacts: Compare fresh-frozen vs. formaldehyde-fixed samples. Nuclear localization is sensitive to overfixation .
Antibody lot variability: Validate with multiple lots (e.g., ab264154 lots 1 and 2 showed consistent IP efficiency) .
Species cross-reactivity: Confirm reactivity using species-specific blocking peptides (tested in mouse/rat/human) .
Technical Recommendations:
Signal amplification: Use tyramide-based systems for IHC in tissues with sparse FOX2 expression.
Pre-absorption: Treat lysates with agarose-bound synthetic peptide (aa 1-50) to reduce background .
Multiplexing: Pair with ER-alpha antibodies to study coregulatory roles in breast cancer models .
Experimental Workflow:
RNA-seq: Profile splicing events in FOX2-knockdown vs. wild-type cells.
Motif analysis: Identify 5'-UGCAUGU-3' enrichment near regulated exons .
Rescue experiments: Express wild-type/mutant FOX2 (e.g., BRCT domain deletions) to test mechanistic requirements .
Example Splicing Target:
| Gene | Exon | FOX2-Dependent Regulation |
|---|---|---|
| TRA2B | E8 | Inclusion (p = 1.2e⁻⁵) |
| CAPN3 | E15 | Skipping (p = 3.8e⁻⁴) |
Critical Factors:
RNase contamination: Always include RNase inhibitors to preserve RNA-protein interactions.
Crosslinker choice: Compare formaldehyde (broad-range) vs. DSP (membrane-permeable) for interaction stability .
Buffer stringency: Optimize NaCl concentrations (150–300 mM) to reduce nonspecific binding.
Integration Strategy: